Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Amarin's request in upcoming court case for Jan

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
studythosestocks Member Profile
 
Followed By 21
Posts 929
Boards Moderated 0
Alias Born 03/09/11
160x600 placeholder
New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scienti... GlobeNewswire Inc. - 10/29/2020 7:00:10 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function a... GlobeNewswire Inc. - 10/26/2020 7:00:10 AM
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderat... GlobeNewswire Inc. - 10/23/2020 7:00:10 AM
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 GlobeNewswire Inc. - 10/19/2020 7:00:10 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interv... GlobeNewswire Inc. - 10/15/2020 4:30:10 PM
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EA... GlobeNewswire Inc. - 10/5/2020 7:00:10 AM
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/9/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:21:33 PM
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation GlobeNewswire Inc. - 9/3/2020 10:51:52 AM
Traders News Source Issues "Potential Home Run" New Research Report InvestorsHub NewsWire - 9/3/2020 9:00:00 AM
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Ri... GlobeNewswire Inc. - 9/1/2020 4:30:10 PM
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ES... GlobeNewswire Inc. - 8/29/2020 3:13:10 AM
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented... GlobeNewswire Inc. - 8/17/2020 7:00:10 AM
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 8/4/2020 6:00:10 AM
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented ... GlobeNewswire Inc. - 7/27/2020 7:00:10 AM
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire Inc. - 7/21/2020 4:15:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/14/2020 5:20:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
studythosestocks   Monday, 12/30/19 02:29:53 PM
Re: None
Post # of 307533 
Amarin's request in upcoming court case for Jan 13th. Taken from Bench Trial Hearing Transcript dated 12/10/19. Notice particularly e,f and g. I think someone posted earlier that there was no chance we got our attorney fees covered or anything else. Amarin is saying that this case is exceptional and asking for attorney fees, cost and expense of the court trial itself and "other relief" that the Court feels appropriate. Looks like little Amarin is not backing down and now the price of not settling by ANDA filers could be a lot more expensive and makes them have to weight their position with a little more scrutinysmile. Not a certainty that we win but definitely AMRN is the heavy favorite this time.

18. In the present case, Case No. 2:15-cv-02525, Plaintiffs seek the following relief:
a. A judgment that Defendants have infringed the Asserted Claims under 35 U.S.C. § 271(e)(2)(A);

b. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any FDA approval of Defendants’ ANDAs is not earlier than the expiration date of the Asserted Patents or any later expiration of exclusivity for the Asserted Patents to which Plaintiffs are or become entitled;

c. A permanent injunction restraining and enjoining Defendants and their officers, agents, servants, employees, parents, subsidiaries, divisions, affiliates, and those persons in active concert or participation with any of them, from making, using, selling, offering to sell, or importing any product that infringes the Asserted Claims, including the products described in Defendants’ ANDAs;

d. A judgment declaring that making, using, selling, offering to sell, or importing the products described in Defendants’ ANDAs, or inducing or contributing to such conduct, would constitute infringement of the Asserted Claims by Defendants pursuant to 35 U.S.C. § 271(a), (b), and/or (c);

e. A finding that this is an exceptional case, and an award of attorney’s fees in this action pursuant to 35 U.S.C. § 285;

f. Costs and expenses in this action; and

g. Such further and other relief as this Court determines to be just and proper.



As a side note, here is what the defendant is asking. C and D look similar returning the heat onto Amarin:

19. Defendants seek the following relief:

a. A judgment declaring that Defendants would not and will not directly, indirectly, contributorily, and/or by inducement, infringe any claim of the Asserted Patents, either literally or under the doctrine of equivalents;

b. A judgment declaring that the claims in the Asserted Patents are invalid for failure to comply with one or more provisions of the Patent Act, 35 U.S.C. §§ 100 et seq.;

c. A judgment awarding Defendants their reasonable costs and attorneys’ fees incurred in connection with this action pursuant to 35 U.S.C. § 285; and

d. Such further and other relief as this Court may deem just and proper.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences